Cas:1198-30-7 1-Isoquinolinecarbonitrile manufacturer & supplier

Chemical Name:1-Isoquinolinecarbonitrile

CAS.NO:1198-30-7

Synonyms:1-Isoquinolinecarbonitrile;isoquinoline-1-carbonitrile;MFCD00134166

Molecular Formula:C₁₀H₆N₂

Molecular Weight:154.168

HS Code:2933499090

Physical and Chemical Properties:

Melting point:90-92 °C(lit.)

Boiling point:348.9±15.0 °C at 760 mmHg

Density:1.2±0.1 g/cm3

Index of Refraction:1.654

PSA:36.68000

Exact Mass:154.053101

LogP:1.74

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:3276

Packing Group:III

Contact us for information like 1-Isoquinolinecarbonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00134166 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,isoquinoline-1-carbonitrile Use and application,isoquinoline-1-carbonitrile technical grade,usp/ep/jp grade.

Related News: The memo denies the company made false statements to the FDA. In their complaint, employees said they were broadly concerned that quality control documents the FDA requires companies to maintain had been rewritten or fabricated. The employees did not specify whether these materials had been shown to the FDA. 1-Isoquinolinecarbonitrile manufacturer Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview. 1-Isoquinolinecarbonitrile supplier Fate Therapeutics has exclusively licensed from MSK foundational intellectual property covering the production and composition of iPSC-derived T cells. 1-Isoquinolinecarbonitrile vendor Fate Therapeutics has exclusively licensed from MSK foundational intellectual property covering the production and composition of iPSC-derived T cells. 1-Isoquinolinecarbonitrile factory Compared with existing Imbruvica therapies, where patients take the BTK inhibitor daily—potentially for years—until their disease progresses, the new Venclexta combo caps treatment at about 14 months. That could offer a new option for “probably younger patients with CLL that prefer more flexible, treatment-free intervals,” said Craig Tendler, M.D., vice president of oncology clinical development and global medical affairs at J&J’s Janssen unit, during an interview.